Latest gross profit for BLPH: $5.6M, below the Healthcare sector average of $67B.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2023
Trailing 12 months ending Sep 30, 2023
Bellerophon Therapeutics (BLPH) currently reports a gross profit of $5.6M as of September 2023. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $67B. Use the charts on this page to explore Bellerophon Therapeutics's gross profit history and peer comparisons.
Bellerophon Therapeutics's gross profit changed from $0 to $5.6M (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Bellerophon Therapeutics's gross profit of $5.6M is lower than the Healthcare sector average of $67B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Bellerophon Therapeutics reported $5.6M in gross profit as of September 2023. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current gross profit of $5.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $67B. From there, open related valuation or income-statement pages for Bellerophon Therapeutics, and consider following BLPH for alerts when major investors trade the stock.